Tag: bird flu

U.S. and South Korean Scientists Lab-Engineer Frankenstein Bird Flu Viruses in Georgia: Journal ‘Virology’

This month, the journal Virology published a study confirming that U.S. researchers at Georgia State University and South Korean collaborators from Jeju National University and Sungshin Women’s University are using reverse genetics to create chimeric H5N1 “Frankenstein” bird flu viruses.

The study was supported by the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) grant AI154656.

Researchers combined purported highly pathogenic avian influenza genes with a laboratory H1N1 backbone.

This is not happening in isolation.

It’s unfolding amid international “pandemic preparedness” efforts, where the creation of dangerous bird flu pathogens goes hand-in-hand with the rollout of vaccines as the supposed solution, which no mainstream or non-mainstream sources are warning about—except this website.

It follows the same playbook as COVID-19, which multiple U.S. agencies have said most likely came from a lab incident.

The new bird flu pathogen creation comes as the United Nations has staged its first-ever global bird flu summit, mobilizing 500 officials and scientists to coordinate “control strategies,” surveillance, and vaccination campaigns—confirming that the very governments engineering these Frankenstein viruses are simultaneously organizing the policies and vaccines that will follow.

Keep reading

Warp Speed 2.0: Trump Administration ACCELERATES Gates-funded, self-amplifying bird flu vaccines

The Trump administration has once again thrown its weight behind controversial vaccine technologies, this time by granting Fast Track designation to ARCT-2304, a self-amplifying mRNA vaccine for H5N1 avian influenza. Developed by Arcturus Therapeutics, this vaccine is part of a broader strategy to prepare for future pandemics, but it also rekindles the contentious legacy of Operation Warp Speed. The Biomedical Advanced Research and Development Authority (BARDA), which played a central role in the rapid development and distribution of COVID-19 vaccines, is once again at the helm, raising serious questions about the safety and efficacy of these experimental technologies.

Key points:

• The Trump administration has granted Fast Track designation to ARCT-2304, a self-amplifying mRNA vaccine for H5N1 avian influenza.

• BARDA, a key player in Operation Warp Speed, is funding and accelerating the development of this next-generation vaccine technology.

• The vaccine, developed by Arcturus Therapeutics, uses self-replicating mRNA that amplifies immune response within the body’s cells.

• The FDA’s Fast Track designation aims to expedite the review process, raising concerns about the rapid deployment of experimental technologies.

• The Gates Foundation has committed $782,543 to support the project, further entrenching the public-private partnership model.

• This fast track explains why Gates and Trump met and had a good three hour meeting after Trump was elected in 2024.

A history of hasty vaccine development

Operation Warp Speed, the Trump administration’s flagship initiative during the early stages of the COVID-19 scandal, was lauded for its speed but criticized for its lack of transparency and the potential risks it posed to public health. The rapid development and emergency authorization of mRNA vaccines from Pfizer-BioNTech and Moderna, while credited with saving lives, also caused significant side effects and the long-term impacts of these novel technologies. The ARCT-2304 vaccine, which uses self-replicating mRNA, is the latest in a series of fast-tracked projects that continue to push the boundaries of what is considered safe and ethical in vaccine development.

The dangers of self-amplifying mRNA technology

Self-amplifying mRNA vaccines, like ARCT-2304, are designed to replicate within the body’s cells, potentially triggering a stronger immune response at lower doses. While this may sound promising, the technology remains largely experimental, and the long-term effects are not yet fully understood. The rapid replication of mRNA within cells could lead to unintended consequences, such as overstimulation of the immune system, which might result in severe adverse reactions. Moreover, the use of self-replicating RNA raises concerns about genetic modification and the potential for unintended genetic changes in the host.

Keep reading

Russia’s Vector Institute Engineers Lab-Made Bird Flu Spike Protein for ‘Needle-Free Jet Injection’: Journal ‘Vaccines’

In new a study published last week in the journal Vaccines, Russia’s Vector Institute detailed how it engineered a lab-built H5 influenza spike protein—chemically optimized for durability and mass expression—under the banner of needle-free jet injection vaccine development.

The study, titled “Immunogenic and Protective Properties of mRNA Vaccine Encoding Hemagglutinin of Avian Influenza A/H5N8 Virus, Delivered by Lipid Nanoparticles and Needle-Free Jet Injection,” confirms yet another link in the chain of international bird flu pandemic countermeasure orchestration.

Lab-Built Hemagglutinin (HA)

The authors openly admit that they deliberately cut away the natural anchor of the bird flu spike and rebuilt it to be secreted outside the cell.

“In brief, the transmembrane and cytoplasmic domains were excised from the native HA sequence. For the purpose of secretion from cells, the signal peptide from the native sequence was retained,” the researchers write.

And further, they took the bird flu spike gene, inserted it into a lab plasmid, and added human RNA control elements plus a long poly(A) tail to boost expression.

“The HA gene, designed based on the native HA gene of the influenza virus A/turkey/Stavropol/320-01/2020 (H5N8) … was cloned into the pVAX-Cas1CC expression cassette … The cassette also contains the human α-globin 5′- and 3′-untranslated regions, as well as a 100-nucleotide poly (A) tail.”

They even confirm the same chemical alteration used in the Pfizer and Moderna COVID-19 shots:

“mRNA synthesis was performed … with uridine replaced by N1-methylpseudouridine.”

Pseudouridine—the synthetic mRNA ingredient swapped in for natural uridine—has now been shown to cause ribosomal “frameshifting” that makes the body attack its own proteins in roughly one-third of recipients, and in other studies has been linked to stimulating cancer growth and metastasis.

Keep reading

Japan Creates Frankenstein Bird Flu Virus With New Immunological Traits

According to a new study published last week in NPJ Vaccines, Japanese researchers engineered an entirely new strain of bird flu, combining the genetic material of two separate wild viruses to create what they call Vac-3: a pathogen that is “a reassortant virus between A/duck/Hokkaido/101/2004 (H5N3) and A/duck/Hokkaido/262/2004 (H6N1).”

This lab-built virus—A/duck/Hokkaido/Vac-3/2007 (H5N1)—was never observed in nature.

It was artificially assembled, grown in eggs, concentrated, and inactivated with formalin to become the whole-particle vaccine used in long-term testing on nonhuman primates.

The new study comes after NIH-funded researchers at the University of Georgia, Mount Sinai, and Texas Biomed were caught engineering lab-made H5N1 bird flu viruses—one of which killed 100% of exposed mammals—using synthetic DNA constructs and then deliberately infecting live dairy cows, all under the same $59 million federal contract that has also been tied to mammal-adapted, drug-resistant strain development.

Japan is also working with U.S. scientists on other projects to build lab-made horse-human influenza hybrids that replicate 100 times faster than natural strains using aborted fetal cells engineered with the cancer-linked SV40 virus, also under the banner of vaccine development.

All of these developments raise fears that another man-made pandemic is on the horizon, as Congress, the White House, the Department of Energy, the FBI, and the CIA have acknowledged that a lab-related incident involving gain-of-function research is most likely the origin of COVID-19.

An Engineered Virus with New Properties

The new Japanese paper highlights that this bird flu Frankenvirus triggered significantly stronger immune responses than existing flu vaccines.

It did so by retaining its full genetic structure, including viral RNA, which stimulated toll-like receptor 7 (TLR7) and a cascade of innate immune activation.

“WPVs contain single-stranded viral RNAs that stimulate innate immune receptors such as toll-like receptor 7,” the authors write.

This means the lab-built virus was left fully intact so it could shock the immune system into overdrive, triggering a much stronger reaction than normal flu shots.

Unlike conventional “split” vaccines, which separate viral proteins from RNA, Japan’s whole-particle vaccine (WPV) preserved the virus’s full anatomy.

This allowed it to activate dendritic cells, induce interferon-producing T cells, and stimulate somatic hypermutation—a powerful, but risky, rewiring of the immune system.

In short, the new virus didn’t just train the immune system—it reprogrammed it.

Keep reading

USDA’s Mass H5N1 Poultry Vaccination Plan Likely to Rely on Leaky Zoetis H5N2 Vaccine

The leading candidate appears to be the Zoetis vaccine targeting H5N2 — even though the dominant strain spreading through U.S. flocks is H5N1 clade 2.3.4.4b.

The vaccine uses the N2 neuraminidase subtype deliberately to support DIVA (Differentiating Infected from Vaccinated Animals) surveillance — allowing authorities to detect field infections in vaccinated birds.

In February 2025, the USDA issued a conditional license to Zoetis for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, specifically for use in chickens, based on a “reasonable expectation of efficacy based on serology data”. In other words, the approval rests on hope that antibody titers will translate into real-world protection—not on demonstrated effectiveness against infection or transmission.

A conditional license allows the vaccine to be used immediately, but only under specific circumstances—such as during an outbreak or in targeted populations. As of June 2025, Zoetis’s H5N2 vaccine remains the only avian influenza vaccine conditionally approved by the USDA for use in U.S. poultry. No other vaccines are currently authorized or ready for large-scale deployment.

However, according to the USDA, inactivated virus vaccines—such as the Zoetis H5N2 formulation—are non-sterilizing in the field. This means they do not prevent infection, do not eliminate viral shedding, and allow vaccinated birds to silently carry and transmit H5N1, particularly in densely populated commercial flocks.

Keep reading

South Korea Lab Makes Bird Flu 100% Lethal in Mammals: ‘Virology Journal’

South Korean scientists have conducted a lab experiment that made a purported wild avian influenza “bird flu” virus 100% lethal in mammals, achieving total death in infected mice by enabling the virus to adapt inside their bodies and spread to others.

The dangerous move comes as the U.S. develops a “next-generation” universal vaccine platform called ‘Generation Gold Standard’ that will focus on avian influenza jab creation, signaling a coordinated international push to engineer and preemptively vaccinate against lab-enhanced bird flu strains with pandemic potential—despite worldwide fallout from similar COVID-era strategies.

Published June 2025 in Virology Journal, the study describes how researchers at Konkuk University infected mice with a highly pathogenic H5N1 avian influenza strain—one that already contained a small percentage (4%) of a mammalian-adaptive mutation known as PB2-E627K.

That tiny minority of mutant virus was enough to take over and kill every infected host.

“All challenged mice died by 8 dpc. Transmission through direct-contact occurred in 100% of cases, and all contact mice died within 12 days.”

This was not an accidental discovery.

Researchers intentionally infected mammals with a virus they knew contained a mutation that helps bird flu spread and replicate more effectively in mammals, including humans.

Once inside the mice, the mutation exploded to near-total dominance—not just in the lungs, but in the brain, where it caused seizures, ataxia, and fatal neurological damage.

“The PB2-E627K variant, initially present at 4% in the virus stock, was selected and reached near-fixation (~ 100%) in the lungs and brains by 6 days post-challenge and was subsequently transmitted.”

“In dead direct-contact mice, the E627K mutation in PB2 was found at a proportion of 99.8–100% in both the lungs and brains.”

The virus became neurotropic—targeting the brain—and caused seizures and other neurological symptoms before death.

Keep reading

Despite Cancellation of Moderna’s mRNA Bird Flu Jab, Efforts for mRNA-LNP H5N1 Jab for Cattle Forges Ahead

Citing a decision based on safety, integrity, and trust connected to a product that “was not scientifically or ethically justifiable,” the US Department of Health and Human Services (HHS) notified Moderna on May 28 that it was terminating the company’s $776 million contract for the development of a bird flu vaccine for humans. That decision is undoubtedly the correct decision. Yet, meanwhile, realizing the danger to humans of the under-tested mRNA technology platform, the US government continues to fund research on H5 influenza mRNA-lipid nanoparticle (LNP) vaccines for use in cattle.

And to make matters worse—and essentially negate the progress made with the termination of HHS’s contract with Moderna—the US Food and Drug Administration (FDA) approved on May 31 a new Moderna COVID-19 mRNA jab called mNEXSPIKE®, which the DARPA partner noted was “for use in all adults 65 and older, as well as individuals 12 through 64 years of age with at least one underlying condition that put them at high risk for severe outcomes from COVID-19.”

While this article ponders the ongoing experimentation with mRNA technology in cattle for bird flu, the FDA’s approval of mNEXSPIKE® is reckless. Meanwhile, as we discuss cattle, the National Institutes of Health (NIH), the US Department of Agriculture (USDA), and the US Department of Energy continue to use federal funding to create mRNA-LNP jabs targeting highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b in Holstein calves. The USDA allocated $824 million in emergency funding in May 2024 to bolster H5N1 efforts, including vaccine development for livestock, with ongoing research to evaluate effectiveness in lactating dairy cattle and eventually other animal species.

To help push the needle forward quickly, a 2025 preprint conducted by researchers at the USDA’s National Animal Disease Center and the University of Pennsylvania—who have received consulting fees from Big Pharma groups, including Pfizer—aims to paint the research in a glowing light, noting that an H5 mRNA-LNP vaccine induced robust antibody and T-cell responses in calves, offering partial protection against H5N1. However, notably, the preprint failed to report biodistribution data, only mentioning intramuscular administration but not whether the mRNA or LNPs were tracked in tissues beyond the intramuscular injection site. But make no mistake. We know that both the mRNA and toxic LNPs can also enter the bloodstream, leading to systemic distribution to organs across the body, including the liver, spleen, heart, and other tissues.

Concerningly, we also know mRNA-LNPs cross the blood-brain barrier, settling into essentially every organ in the human body, causing damage to the brain, heart, liver, and bone marrow in humans. Why isn’t this deadly hazard being studied in cattle? Thus far, no studies have directly quantified H5 mRNA-LNP biodistribution in cattle, particularly in lactating dairy cows, where H5N1 replication in the mammary glands raises significant concerns about milk safety.

Keep reading

USDA ends ‘maximum pain bird flu gain-of-function experiments’ with Wuhan lab parent

The U.S. Department of Agriculture canceled its $1 million collaboration with the Chinese Academy of Sciences, the parent to the Wuhan Institute of Virology, to conduct gain-of-function experiments on bird flu viruses, Secretary Brooke Rollins told Rep. Ben Cline, R-Va.

Speaking at a House Agriculture Appropriations Subcommittee hearing, Rollins said “it is my understanding that those [experiments] have been discontinued just in the last few months” when Cline asked for their status, started in the Biden administration, and that if she’s wrong, “then 100%, yes,” USDA will stop them.

Cline said her predecessor Tom Vilsack “defended and distorted this risky research” when Vilsack testified, denying it was a “collaboration” even though the “project title” calls it that and claiming there was no “data sharing” even though public records show USDA visiting the China lab to “share results on site.” The Chinese researcher lists the Wuhan Institute of Virology as an affiliation, Cline said.

“It is outrageous that U.S. taxpayer dollars were ever used by the Biden USDA to fund joint experiments with the Chinese Communist Party, especially research that could be catastrophic if mishandled or weaponized,” Cline said in a statement.

The White Coat Waste Project, which exposed through public records requests the five-year project on what it called “maximum pain bird flu gain-of-function experiments” on birds as young as a day old, cheered Rollins’ declaration.

“Taxpayers shouldn’t be forced to pay for the creation of pandemic-causing pathogens, and now, following a White Coat Waste campaign, they won’t have to,” President Anthony Bellotti said.

Keep reading

Why the Canadian Govt and Big Pharma are Waging War on an Ostridge Farm

Canada’s Ostrich Cull Scandal: Are Big Pharma and Globalist Interests Pulling the Strings?
When I first heard about the ostrich farm in Edgewood, British Columbia, facing a forced cull of 400 ostriches, something immediately felt off. Sure, authorities claim they’re responding to an avian flu outbreak—but the deeper I dig into this, the more it smells of something else entirely. Let’s get right into it, because this isn’t just about bird flu—this is about science, censorship, profits, and powerful global interests that seem determined to control the narrative and crush alternatives.

The Edgewood Ostrich Outrage: How We Got Here

Picture a remote, idyllic farm in British Columbia’s Kootenay region, home to about 400 ostriches on 65 acres. On December 31, 2024, two ostriches tragically die of H5N1 avian flu, reportedly brought by wild migratory birds. This leads to a swift quarantine by the Canadian Food Inspection Agency (CFIA)—but that’s just the beginning.

Incredibly, after the initial outbreak, only about 40 birds (roughly 10% of the flock, mainly younger ostriches) succumb to the virus. Within just days, something remarkable occurs: the flock stabilizes, and the remaining 90% of the birds are thriving. Farm owner Karen Espersen observes that these ostriches seem to develop immunity, something clearly special and scientifically fascinating.

Yet despite the farm’s desperate pleas for additional testing and careful scientific study, the CFIA orders all ostriches culled—every last healthy bird—to supposedly “prevent the spread.” The family fights back, but on May 13, 2025, the Canadian Federal Court sides with the CFIA, leaving no room for appeal. The ostriches, despite clear evidence of recovery and possible immunity, are condemned to death.

Why the rush to destroy animals that might be holding keys to groundbreaking treatments? Why no interest in studying them further?

Keep reading

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Apr. 10, 2025– Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype contained in the vaccine. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1, a significant global health risk. The Phase 1 clinical study initiated in November 2024.

Fast Track Designation from the FDA is granted to vaccines intended to prevent serious conditions caused by infectious disease. The designation is designed to expedite the development and review process, providing several benefits, including enhanced communication with the FDA and eligibility for priority review, and the possibility of a rolling review.

“We are pleased to receive Fast Track Designation from the FDA for ARCT-2304,” said Joseph Payne, President and CEO of Arcturus Therapeutics. “We remain steadfast in our commitment to the U.S. government to develop safe and effective STARR® next-generation mRNA vaccines to protect U.S. citizens from future pandemic threats. This designation from the FDA is an important step forward in our mission to provide protective solutions for global health crises.”

This project has been supported in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C0007.

Keep reading